Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 3/20 | 0.48 |
| ▸ | TACR1 | P25103 | 3/20 | 0.48 |
| ▸ | TACR3 | P29371 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7494916 | 1.00 | TACR2 (0.48) | TACR2TACR1TACR3HRH1 | |
| SCHEMBL7497839 | 0.95 | TACR2 (0.47) | TACR2TACR1TACR3HRH1 | |
| SCHEMBL7499055 | 0.95 | TACR2 (0.47) | TACR2TACR1TACR3HRH1 | |
| SCHEMBL7497834 | 0.95 | TACR2 (0.47) | TACR2TACR1TACR3HRH1 | |
| SCHEMBL7495030 | 0.91 | TACR2 (0.46) | TACR2TACR1TACR3HRH1 | |
| SCHEMBL3987149 | 0.91 | TACR2 (0.46) | TACR2TACR1TACR3HRH1 | |
| SCHEMBL3980098 | 0.91 | TACR2 (0.46) | TACR2TACR1TACR3HRH1 | |
| SCHEMBL3982017 | 0.91 | TACR2 (0.51) | TACR2TACR1TACR3HRH1 | |
| SCHEMBL3982014 | 0.91 | TACR2 (0.51) | TACR2TACR1TACR3HRH1 | |
| SCHEMBL3980991 | 0.90 | TACR2 (0.45) | TACR2TACR1TACR3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560549-B2 | Sulfonyloxy derivatives | SANKYO COMPANY, LIMITED (JP) | 2009-07-14 | — | — | US | disclosed |
| US-7560549-B2 | Sulfonyloxy derivatives | SANKYO COMPANY, LIMITED (JP) | 2009-07-14 | — | — | US | disclosed |
| US-20070135434-A1 | Sulfonyloxy derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
| US-20070135434-A1 | Sulfonyloxy derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1754701-A1 | SULFONYLOXY DERIVATIVES | Sankyo Company, Limited (JP) | 2007-02-21 | — | — | EP | disclosed |
| EP-1057827-B1 | SPIROPIPERIDINE DERIVATIVES | SANKYO CO (JP) | 2003-09-10 | — | — | EP | disclosed |
| EP-0987269-B1 | SALTS OF OPTICALLY ACTIVE SULFOXIDE DERIVATIVE | SANKYO CO (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-6511975-B1 | Exhibit antagonistic action against tachykinin receptors | SANKYO COMPANY, LIMITED (JP) | 2003-01-28 | — | — | US | disclosed |
| US-6448247-B1 | TACHYKININ RECEPTOR ANTAGONIST; ESPECIALLY TO THE RECEPTORS FOR SUBSTANCE P (WHICH RECEPTORS ARE GENERALLY REFERRED TO AS ?NEUROKININ 1 RECEPTORS?) | SANKYO COMPANY, LIMITED (JP) | 2002-09-10 | — | — | US | disclosed |
| US-6362179-B1 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEM DISORDERS | SANKYO COMPANY, LIMITED (JP) | 2002-03-26 | — | — | US | disclosed |
| EP-0776893-B1 | Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2 | SANKYO CO (JP) | 2002-02-27 | — | — | EP | disclosed |
| US-6159967-A | Heterocyclic compounds having tachykinin receptor antagonist activity their preparation and their use | SANKYO COMPANY, LIMITED (JP) | 2000-12-12 | — | — | US | disclosed |
| EP-1057827-A1 | SPIROPIPERIDINE DERIVATIVES | Sankyo Company Limited (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-0987269-A1 | SALTS OF OPTICALLY ACTIVE SULFOXIDE DERIVATIVE | Sankyo Company Limited (JP) | 2000-03-22 | — | — | EP | disclosed |
| EP-0776893-A1 | Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2 | SANKYO COMPANY LIMITED (JP) | 1997-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135434-A1 | Sulfonyloxy derivatives | TACR1, NPSR1, TACR2 | TACR2 3/4885TACR1 1/4885TACR3 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.